The DOI matches its Crossref record; 32 of the 34 references it cites were found in a registry or an index.
NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Open accessAbstract
Alzheimer’s disease is the world’s most common dementing illness. Deposition of amyloid-β peptide drives cerebral neuroinflammation by activating microglia. Indeed, amyloid-β activation of the NLRP3 inflammasome in microglia is fundamental for interleukin-1β maturation and subsequent inflammatory events. However, it remains unknown whether NLRP3 activation contributes to Alzheimer’s disease in vivo. Here we demonstrate strongly enhanced active caspase-1 expression in human mild cognitive impairment and brains with Alzheimer’s disease, suggesting a role for the inflammasome in this neurodegenerative disease. Nlrp3−/− or Casp1−/− mice carrying mutations associated with familial Alzheimer’s disease were largely protected from loss of spatial memory and other sequelae associated with Alzheimer’s disease, and demonstrated reduced brain caspase-1 and interleukin-1β activation as well as enhanced amyloid-β clearance. Furthermore, NLRP3 inflammasome deficiency skewed microglial cells to an M2 phenotype and resulted in the decreased deposition of amyloid-β in the APP/PS1 model of Alzheimer’s disease. These results show an important role for the NLRP3/caspase-1 axis in the pathogenesis of Alzheimer’s disease, and suggest that NLRP3 inflammasome inhibition represents a new therapeutic intervention for the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rat research has identified the NLRP3-ASC inflammasome as a major mechanism through which microglia may drive pathological features of AD [92,93,94].”
From The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders (2023) · cites this paper as [92]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both beta-amyloids and tau can activate the NLRP3-ASC inflammasome within microglia [92,93].”
From The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders (2023) · cites this paper as [92]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The nucleotide-binding oligomerization domain-like receptor, pyrin domain-containing 3 (NLRP3), within microglia recruits the adaptor protein apoptosis-associated speck-like protein containing a C-terminal caspase recruitment domain (ASC) to form an inflammasome complex.”
From The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders (2023) · cites this paper as [92]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In APP/PS1 mice model, NLRP3 knockout reduced Aβ deposition by enhancing phagocytic clearance capacity and increasing extracellular Aβ degradation by insulin- degrading enzyme (IDE).354”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [354]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The activation of hippocampal NLRP3 inflammasome-mediated pyroptosis is associated with neuronal damage, cognitive decline, and neuronal death (Hanslik & Ulland, 2020; Heneka et al., 2013; Ising et al., 2019; Venegas et al., 2017).”
From Picroside II Alleviates the Progression of Alzheimer’s Disease via the NLRP3/Caspase-1/GSDMD Pathway (2025) · cites this paper as Heneka et al., 2013
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NLRP3 or caspase-1 knockdown in AD mouse models has yielded promising results in decreasing Aβ accumulation, improving spatial memory, and alleviating other AD-related symptoms (Heneka et al., 2013).”
From Picroside II Alleviates the Progression of Alzheimer’s Disease via the NLRP3/Caspase-1/GSDMD Pathway (2025) · cites this paper as Heneka et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ablation of Nlrp3 or Casp1 in APP/PS1 mice rescued spatial memory and behavioral deficits, LTP suppression and spine loss observed in these mice [77].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, another study reported strongly increased levels of active caspase-1 in early-onset AD and LOAD patients as well as in MCI individuals [77].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [77]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This inflammasome complex is responsible for the production of IL-1 beta, which is a proinflammatory cytokine.”
From The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders (2023) · cites this paper as [92]
The cited source says what the claim attributes to it.
In the citing paper
“IL-1 beta was shown to exacerbate tau pathologies [97] and reduce microglial phagocytic activity [92,93,94].”
From The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders (2023) · cites this paper as [92]
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, microglial function may also be of relevance to cognitive performance, as suggested by recent experimental data, which showed that improved microglial clearance was protective in terms of memory function (17).”
From SUCLG2 identified as both a determinator of CSF Aβ1–42 levels and an attenuator of cognitive decline in Alzheimer's disease (2014) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“Proinflammatory environments and signalling are a prominent observation in AD brain pathology [39].”
From Heterozygous expression of the Alzheimer’s disease-protective PLCγ2 P522R variant enhances Aβ clearance while preserving synapses (2022) · cites this paper as [39]
The cited source says what the claim attributes to it.
In the citing paper
“Inhibiting or downregulating the NLRP3 inflammasome ameliorates AD neuropathology in animal models, which opens up a therapeutic avenue for modulators of NLRP3 activation in AD.”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [77]
The cited source says what the claim attributes to it.
In the citing paper
“APP/PS1/Nlrp3−/− and APP/PS1/Casp1−/− mice also displayed decreased Aβ plaque deposition, suggesting that NLRP3 inflammasome activation impairs microglial capacity to clear Aβ [77].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [77]
The cited source says what the claim attributes to it.
In the citing paper
“APP/PS1/Nlrp3−/− and APP/PS1/Casp1−/− mice also displayed decreased Aβ plaque deposition, suggesting that NLRP3 inflammasome activation impairs microglial capacity to clear Aβ [77].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [77]
The cited source says what the claim attributes to it.
In the citing paper
“The decreased plaque deposition was also related to increased levels of the proteolytic enzyme insulin-degrading enzyme (IDE) [77], previously reported to degrade Aβ [83].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [77]
The cited source says what the claim attributes to it.
In the citing paper
“NLRP3 deficiency reduces amyloid deposition and rescues memory deficits in the APP/PS1 model of AD [18].”
From 25-Hydroxycholesterol amplifies microglial IL-1β production in an apoE isoform-dependent manner (2020) · cites this paper as [18]
In the citing paper
“One of the key biological functions of CASP1 is the cleavage of prointerleukin-1β (IL-1β) into the mature biological active cytokine, which is largely overexpressed in brains of patients with AD.44”
From APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer’s disease (2016) · cites this paper as [44]
In the citing paper
“Preclinical studies support the concept that CASP1-directed increase of IL-1β can augment the deposition of β-amyloid within the brain to worsen Alzheimer's symptoms.44”
From APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer’s disease (2016) · cites this paper as [44]
In the citing paper
“CASP1, an essential component of NLPR3 inflammasomes, encodes a cysteine protease that is largely overexpressed in brains of patients with AD.44”
From APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer’s disease (2016) · cites this paper as [44]
In the citing paper
“Notably, Aβ also can activate NF-κB signaling and the NLRP3-ASC inflammasome [426, 427], suggesting that Aβ and tau share common mechanisms in microglia activation.”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [427]
In the citing paper
“The NLRP3 inflammasome is critical for maturation of IL-1β, and loss of NLRP3 in APP/PS1 decreased amyloid burden (131).”
From Microglia in Alzheimer's disease (2017) · cites this paper as [131]
In the citing paper
“Microglia express multiple receptors that can bind Aβ and trigger inflammation, such as CD36 (105), TLR2, TLR4, TLR6 (17), and NLRP3 (106)”
From Microglia Function in the Central Nervous System During Health and Neurodegeneration (2017) · cites this paper as [106]
In the citing paper
“NLRP3 and caspase-1 genetic deletion results in decreased Aβ deposition, reduced IL-1β release from microglia and improved cognitive performance in APPPS1 mice (Heneka et al., 2013).”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Heneka et al., 2013
In the citing paper
“Toll-like receptors and NOD-like receptors have been previously implicated in the microglia response to Aβ accumulation and shown to mediate an inflammatory response that contributes to pathology”
From TREM2 Maintains Microglial Metabolic Fitness in Alzheimer’s Disease (2017) · cites this paper as Heneka et al., 2013
In the citing paper
“ITGAM/CD11b (or CR3A), is a cell surface receptor involved in activation, migration and phagocytosis of immune cells, so much so that ITGAM/CD11b is used as a marker of activated microglia (Matsuoka et al., 2001; Heneka et al., 2013; Kamphuis et al., 2016).”
From Genetic variability in response to amyloid beta deposition influences Alzheimer’s disease risk (2019) · cites this paper as Heneka et al., 2013
In the citing paper
“Animal studies confirmed this significant involvement of NLRP activation, as APP/PS1 mice, lacking the expression of ASC, caspase-1, or NLRP3 had significantly reduced hippocampal and cortical amyloid plaque deposition and ameliorated disease outcome (229, 230).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [230]
In the citing paper
“Recently, an alternative pathway has been described for intracellular signaling produced by the binding of Aβ to microglial cells, activating NLRP3 inflammasome (Heneka et al., 2013; Sheedy et al., 2013).”
From The role of microglia in retinal neurodegeneration: Alzheimer’s disease, parkinson, and glaucoma. (2017) · cites this paper as Heneka et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A synaptic model of memory: long-term potentiation in the hippocampus
Bliss, T. V. P., & Collingridge, G. L. (1993) · Nature · doi:10.1038/361031a0 · Cited by 11,566
The NALP3 inflammasome is involved in the innate immune response to amyloid-β
Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T., Fitzgerald, K. A., Latz, E., Moore, K. J., & Golenbock, D. T. (2008) · Nature Immunology · doi:10.1038/ni.1636 · Cited by 2,441
Self-citationThe Inflammasomes: Guardians of the Body
Martinon, F., Mayor, A., & Tschopp, J. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132715 · Cited by 2,436
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Li, P., Allen, H., Banerjee, S., Franklin, S., Herzog, L., Johnston, C. G., McDowell, J., Paskind, M. P., Rodman, L., Salfeld, J. G., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90490-5 · Cited by 1,408
Microglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice
Hickman, S. E., Allison, E. K., & El Khoury, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0616-08.2008 · Cited by 1,329 · cited 1×
“Cytokines, including IL-1 β , were found to impair microglial clearance functions 16,17 .”
Bevins, R. A., & Besheer, J. (2006) · Nature Protocols · doi:10.1038/nprot.2006.205 · Cited by 1,278
Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3
Kanneganti, T., Özören, N., Body–Malapel, M., Amer, A. O., Park, J., Franchi, L., Whitfield, J. R., Barchet, W., Colonna, M., Vandenabeele, P., et al. (2006) · Nature · doi:10.1038/nature04517 · Cited by 1,149
Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice
Chapman, P. F., White, G. L., Jones, M. W., Cooper-Blacketer, D., Marshall, V. J., Irizarry, M., Younkin, L., Good, M. A., Bliss, T. V. P., Hyman, B. T., et al. (1999) · Nature Neuroscience · doi:10.1038/6374 · Cited by 946
El Khoury, J., Toft, M., Hickman, S. E., Means, T. K., Terada, K., Geula, C., & Luster, A. D. (2007) · Nature Medicine · doi:10.1038/nm1555 · Cited by 915
Cited by
Sorted by citations
Items 101–200 of 1,031
Norden, D. M., Muccigrosso, M. M., & Godbout, J. P. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.10.028 · Cited by 413
Pan, Y., Chen, X.-Y., Zhang, Q.-Y., & Kong, L.-D. (2014) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2014.04.007 · Cited by 405
Glial contributions to neurodegeneration in tauopathies
Leyns, C. E. G., & Holtzman, D. M. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0192-x · Cited by 409
NLR members NLRC4 and NLRP3 mediate sterile inflammasome activation in microglia and astrocytes
Freeman, L., Guo, H., David, C. N., Brickey, W. J., Jha, S., & Ting, J. P.-Y. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20150237 · Cited by 397
Autophagy in microglia degrades extracellular β-amyloid fibrils and regulates the NLRP3 inflammasome
Cho, M.-H., Cho, K., Kang, H.-J., Jeon, E.-Y., Kim, H.-S., Kwon, H.-J., Kim, H.-M., Kim, D.-H., & Yoon, S.-Y. (2014) · Autophagy · doi:10.4161/auto.29647 · Cited by 395
Microglia and astrocyte dysfunction in parkinson's disease
Kam, T., Hinkle, J. T., Dawson, T. M., & Dawson, V. L. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105028 · Cited by 420
Pathogenesis, diagnostics, and therapeutics for Alzheimer's disease: Breaking the memory barrier
Tryphena, K. P., Shukla, R., Khatri, D. K., & Vora, L. K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102481 · Cited by 438
TLR4 Cross-Talk With NLRP3 Inflammasome and Complement Signaling Pathways in Alzheimer's Disease
Yang, J., Wise, L., & Fukuchi, K.-I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00724 · Cited by 387
Jin, X., Liu, M., Zhang, D., Zhong, X., Du, K., Qian, P., Yao, W., Gao, H., & Wei, M. (2019) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13086 · Cited by 399
Mitochondria-associated membranes (MAMs) and inflammation
Missiroli, S., Patergnani, S., Caroccia, N., Pedriali, G., Perrone, M., Previati, M., Wieckowski, M. R., & Giorgi, C. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0027-2 · Cited by 398
Lucin, K. M., O’Brien, C. E., Bieri, G., Czirr, E., Mosher, K. I., Abbey, R. J., Mastroeni, D. F., Rogers, J., Spencer, B., Masliah, E., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.06.046 · Cited by 374
Ubiquitin signalling in neurodegeneration: mechanisms and therapeutic opportunities
Schmidt, M. F., Gan, Z. Y., Komander, D., & Dewson, G. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-020-00706-7 · Cited by 379
Zhong, L., Xu, Y., Zhuo, R., Wang, T., Wang, K., Huang, R., Wang, D., Gao, Y., Zhu, Y., Sheng, X., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09118-9 · Cited by 371
NLRP3 inflammasome is expressed and functional in mouse brain microglia but not in astrocytes
Gustin, A., Kirchmeyer, M., Koncina, E., Felten, P., Losciuto, S., Heurtaux, T., Tardivel, A., Heuschling, P., & Dostert, C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130624 · Cited by 369
IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline
Fu, A. K. Y., Hung, K.-W., Yuen, M. Y. F., Zhou, X., Mak, D. S. Y., Chan, I. C. W., Cheung, T. H., Zhang, B., Fu, W.-Y., Liew, F. Y., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1604032113 · Cited by 369
Webers, A., Heneka, M. T., & Gleeson, P. A. (2019) · Immunology and Cell Biology · doi:10.1111/imcb.12301 · Cited by 377
Self-citationDrugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets
Walle, L. V., & Lamkanfi, M. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00822-2 · Cited by 397
Salminen, A., Kaarniranta, K., Kauppinen, A., Ojala, J. O., Haapasalo, A., Soininen, H. S., & Hiltunen, M. O. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.06.002 · Cited by 371
Luo, R., Su, L.-Y., Li, G., Yang, J., Liu, Q., Yang, L.-X., Zhang, D.-F., Zhou, H., Xu, M., Fan, Y., et al. (2020) · Autophagy · doi:10.1080/15548627.2019.1596488 · Cited by 364
Tang, T., Lang, X., Xu, C., Wang, X., Gong, T., Yang, Y., Cui, J., Bai, L., Wang, J., Jiang, W., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00227-x · Cited by 375
Chakrabarty, P., Li, A., Ceballos-Diaz, C., Eddy, J. A., Funk, C. C., Moore, B., DiNunno, N., Rosario, A. M., Cruz, P. E., Verbeeck, C., et al. (2015) · Neuron · doi:10.1016/j.neuron.2014.11.020 · Cited by 354
Islet inflammation in type 2 diabetes and physiology
Eguchi, K., & Nagai, R. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88877 · Cited by 374
Bisht, K., Sharma, K. P., & Tremblay, M. (2018) · Neurobiology of Stress · doi:10.1016/j.ynstr.2018.05.003 · Cited by 366
Transcriptional signature in microglia associated with Aβ plaque phagocytosis
Grubman, A., Choo, X. Y., Chew, G., Ouyang, J. F., Sun, G., Croft, N. P., Rossello, F. J., Simmons, R., Buckberry, S., Landin, D. V., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23111-1 · Cited by 357
Boza-Serrano, A., Ruiz, R., Sanchez-Varo, R., García-Revilla, J., Yang, Y., Jimenez-Ferrer, I., Paulus, A., Wennström, M., Vilalta, A., Allendorf, D., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02013-z · Cited by 357
Microbiota-derived short chain fatty acids modulate microglia and promote Aβ plaque deposition
Colombo, A. V., Sadler, R. K., Llovera, G., Singh, V., Roth, S., Heindl, S., Sebastian Monasor, L., Verhoeven, A., Peters, F., Parhizkar, S., et al. (2021) · eLife · doi:10.7554/elife.59826 · Cited by 354
Sankowski, R., Mader, S., & Valdés-Ferrer, S. I. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00028 · Cited by 351
Inflammation in Alzheimer’s disease: Lessons learned from microglia-depletion models
Spangenberg, E. E., & Green, K. N. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.07.003 · Cited by 352
Cai, Y., Liu, J., Wang, B., Sun, M., & Yang, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.856376 · Cited by 351
Systemic inflammation impairs microglial Aβ clearance through NLRP3 inflammasome
Tejera, D., Mercan, D., Sanchez‐Caro, J. M., Hanan, M., Greenberg, D., Soreq, H., Latz, E., Golenbock, D., & Heneka, M. T. (2019) · The EMBO Journal · doi:10.15252/embj.2018101064 · Cited by 351
Self-citationProgrammed Necrosis in the Cross Talk of Cell Death and Inflammation
Chan, F. K.-M., Luz, N. F., & Moriwaki, K. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112248 · Cited by 359
DAMPs, MAMPs, and NAMPs in plant innate immunity
Choi, H. W., & Klessig, D. F. (2016) · BMC Plant Biology · doi:10.1186/s12870-016-0921-2 · Cited by 378
Tau and neuroinflammation: what impact for Alzheimer's disease and tauopathies?
Laurent, C., Buée, L., & Blum, D. (2018) · Biomedical Journal · doi:10.1016/j.bj.2018.01.003 · Cited by 348
Amyloid-β induces NLRP1-dependent neuronal pyroptosis in models of Alzheimer’s disease
Tan, M.-S., Tan, L., Jiang, T., Zhu, X.-C., Wang, H.-F., Jia, C.-D., & Yu, J. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.348 · Cited by 351
Doens, D., & Fernández, P. L. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-48 · Cited by 348
Microglia Phenotypes in Aging and Neurodegenerative Diseases
Wendimu, M. Y., & Hooks, S. B. (2022) · Cells · doi:10.3390/cells11132091 · Cited by 336
Type 2 diabetes as a protein misfolding disease
Mukherjee, A., Morales‐Scheihing, D., Butler, P. C., & Soto, C. A. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.04.005 · Cited by 349
Fiery Cell Death: Pyroptosis in the Central Nervous System
McKenzie, B., Dixit, V. M., & Power, C. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2019.11.005 · Cited by 341
Exercise benefits on Alzheimer’s disease: State-of-the-science
Valenzuela, P. L., Castillo-García, A., Morales, J. S., de la Villa, P., Hampel, H., Emanuele, E., Lista, S., & Lucia, A. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101108 · Cited by 337
Yue, N., Huang, H., Zhu, X., Han, Q., Wang, Y., Li, B., Liu, Q., Wu, G., Zhang, Y., & Yu, J. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0865-y · Cited by 334
The therapeutic potential of targeting regulated non-apoptotic cell death
Hadian, K., & Stockwell, B. R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00749-8 · Cited by 349
The Impact of Systemic Inflammation on Alzheimer’s Disease Pathology
Xie, J., Van Hoecke, L., & Vandenbroucke, R. E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.796867 · Cited by 324
Functions of NOD-Like Receptors in Human Diseases
Zhong, Y., Kinio, A. E., & Saleh, M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00333 · Cited by 337
Lee, J. K., & Kim, N. (2017) · Molecules · doi:10.3390/molecules22081287 · Cited by 326
Innate Immunity and Neurodegeneration
Labzin, L. I., Heneka, M. T., & Latz, E. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-050715-104343 · Cited by 319
Self-citationExosome-like Nanoparticles from Ginger Rhizomes Inhibited NLRP3 Inflammasome Activation
Chen, X., Zhou, Y., & Yu, J. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00246 · Cited by 322
Ershaid, N., Sharon, Y., Doron, H., Raz, Y., Shani, O., Cohen, N., Monteran, L., Leider–Trejo, L., Ben‐Shmuel, A., Yassin, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12370-8 · Cited by 323
The pathogenic role of the inflammasome in neurodegenerative diseases
Freeman, L. C., & Ting, J. P. ‐. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13217 · Cited by 276
NLRP3 Inflammasome and Inflammatory Diseases
Wang, Z., Zhang, S., Xiao, Y., Zhang, W., Wu, S., Qin, T., Yue, Y., Qian, W., & Li, L. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/4063562 · Cited by 321
The IL-1β phenomena in neuroinflammatory diseases
Mendiola, A. S., & Cardona, A. E. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1732-9 · Cited by 328
The identity and function of microglia in neurodegeneration
Song, W. M., & Colonna, M. (2018) · Nature Immunology · doi:10.1038/s41590-018-0212-1 · Cited by 308
The effects of microglia-associated neuroinflammation on Alzheimer’s disease
Wang, C., Zong, S., Cui, X., Wang, X., Wu, S., Wang, L., Liu, Y., & Lu, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1117172 · Cited by 331
NLRP3 inflammasome in neuroinflammation and central nervous system diseases
Xu, W., Huang, Y., & Zhou, R. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01275-w · Cited by 355
The role of inflammasomes in kidney disease
Komada, T., & Muruve, D. A. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0158-z · Cited by 317
Microglia in Health and Disease
Ransohoff, R. M., & Khoury, J. E. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020560 · Cited by 303
Proton-driven transformable nanovaccine for cancer immunotherapy
Gong, N., Zhang, Y., Teng, X., Wang, Y., Huo, S., Qing, G., Ni, Q., Li, X., Wang, J., Ye, X., et al. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-00782-3 · Cited by 300
Lonnemann, N., Hosseini, S., Marchetti, C., Skouras, D. B., Stefanoni, D., D’Alessandro, A., Dinarello, C. A., & Korte, M. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2009680117 · Cited by 298
Microglia in Alzheimer Disease: Well-Known Targets and New Opportunities
Hemonnot, A.-L., Hua, J., Ulmann, L., & Hirbec, H. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00233 · Cited by 298
Kaushal, V, Dye, R., Pakavathkumar, P., Foveau, B., Flores, J., Hyman, B., Ghetti, B., Koller, B. H., & LeBlanc, A. C. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2015.16 · Cited by 297
Emerging roles of innate and adaptive immunity in Alzheimer’s disease
Chen, X., & Holtzman, D. M. (2022) · Immunity · doi:10.1016/j.immuni.2022.10.016 · Cited by 297
Sengupta, U., & Kayed, R. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102270 · Cited by 318
NLRP3 at the interface of metabolism and inflammation
Haneklaus, M., & O'Neill, L. A. J. (2015) · Immunological Reviews · doi:10.1111/imr.12285 · Cited by 296
The Inflammasomes and Autoinflammatory Syndromes
Broderick, L., Nardo, D. D., Franklin, B. S., Hoffman, H. M., & Latz, E. (2014) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040431 · Cited by 304
Self-citationActivation of innate immune cGAS-STING pathway contributes to Alzheimer’s pathogenesis in 5×FAD mice
Xie, X., Ma, G., Li, X., Zhao, J., Zhao, Z., & Zeng, J. (2023) · Nature Aging · doi:10.1038/s43587-022-00337-2 · Cited by 292
LncRNA H19 initiates microglial pyroptosis and neuronal death in retinal ischemia/reperfusion injury
Wan, P., Su, W., Zhang, Y., Li, Z., Deng, C., Li, J., Jiang, N., Huang, S., Long, E., & Zhuo, Y. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0351-4 · Cited by 289
Focus on the Role of NLRP3 Inflammasome in Diseases
Fusco, R., Siracusa, R., Genovese, T., Cuzzocrea, S., & Paola, R. D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124223 · Cited by 301
Microglia actions in Alzheimer's disease
Prokop, S., Miller, K. R., & Heppner, F. L. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1182-x · Cited by 291
Flores, J., Noël, A., Foveau, B., Lynham, J., Lecrux, C., & LeBlanc, A. C. (2018) · Nature Communications · doi:10.1038/s41467-018-06449-x · Cited by 288
Regulation of cGAS–STING signalling and its diversity of cellular outcomes
Zhang, Z., & Zhang, C. (2025) · Nature Reviews Immunology · doi:10.1038/s41577-024-01112-7 · Cited by 287
The good, the bad, and the opportunities of the complement system in neurodegenerative disease
Schartz, N. D., & Tenner, A. J. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02024-8 · Cited by 298
Sarkar, S., Malovic, E., Harischandra, D. S., Ghaisas, S., Panicker, N., Charli, A., Palanisamy, B. N., Rokad, D., Jin, H., Anantharam, V., et al. (2017) · npj Parkinson s Disease · doi:10.1038/s41531-017-0032-2 · Cited by 288
Lopez‐Rodriguez, A. B., Hennessy, E., Murray, C. L., Nazmi, A., Delaney, H. J., Healy, D., Fagan, S. G., Rooney, M., Stewart, E., Lewis, A., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12341 · Cited by 293
Johann, S., Heitzer, M., Kanagaratnam, M., Goswami, A., Rizo, T., Weis, J., Troost, D., & Beyer, C. (2015) · Glia · doi:10.1002/glia.22891 · Cited by 285
Neuroinflammation in Alzheimer’s disease
Zhang, F., & Jiang, L. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s75546 · Cited by 276
Drivers of age‐related inflammation and strategies for healthspan extension
Goldberg, E. L., & Dixit, V. D. (2015) · Immunological Reviews · doi:10.1111/imr.12295 · Cited by 274
He, Y., Varadarajan, S., Muñoz-Planillo, R., Burberry, A., Nakamura, Y., & Núñez, G. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.515080 · Cited by 275
AIM2 and NLRC4 inflammasomes contribute with ASC to acute brain injury independently of NLRP3
Dénes, Á., Coutts, G., Lénárt, N., Cruickshank, S. M., Pelegrín, P., Skinner, J., Rothwell, N. J., Allan, S. M., & Brough, D. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419090112 · Cited by 277
Neuronal hyperactivity--A key defect in Alzheimer’s disease?
Busche, M. A., & Konnerth, A. (2015) · BioEssays · doi:10.1002/bies.201500004 · Cited by 266
Physical Exercise Inhibits Inflammation and Microglial Activation
Mee-inta, O., Zhao, Z., & Kuo, Y. (2019) · Cells · doi:10.3390/cells8070691 · Cited by 285
Alfonso-Loeches, S., Ureña-Peralta, J. R., Morillo-Bargues, M. J., Oliver-De La Cruz, J., & Guerri, C. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00216 · Cited by 265
Hormones and diet, but not body weight, control hypothalamic microglial activity
Gao, Y., Ottaway, N., Schriever, S. C., Legutko, B., García‐Cáceres, C., de la Fuente, E., Mergen, C., Bour, S., Thaler, J. P., Seeley, R. J., et al. (2013) · Glia · doi:10.1002/glia.22580 · Cited by 263
Innate Immune Cell Death in Neuroinflammation and Alzheimer’s Disease
Rajesh, Y., & Kanneganti, T. (2022) · Cells · doi:10.3390/cells11121885 · Cited by 269
Fyn kinase regulates misfolded α-synuclein uptake and NLRP3 inflammasome activation in microglia
Panicker, N., Sarkar, S., Harischandra, D. S., Neal, M. P., Kam, T., Jin, H., Saminathan, H., Langley, M. R., Charli, A., Samidurai, M., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20182191 · Cited by 257
β-Hydroxybutyrate inhibits inflammasome activation to attenuate Alzheimer’s disease pathology
Shippy, D. C., Wilhelm, C. R., Viharkumar, P. A., Raife, T. J., & Ulland, T. K. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01948-5 · Cited by 266
Priming Microglia for Innate Immune Memory in the Brain
Neher, J. J., & Cunningham, C. M. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.001 · Cited by 263
Moonen, S., Koper, M. J., Schoor, E. V., Schaeverbeke, J. M., Vandenberghe, R. R., Arnim, C. A. F. V., Tousseyn, T., Strooper, B. D., & Thal, D. R. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02528-y · Cited by 268
How location and cellular signaling combine to activate the NLRP3 inflammasome
Akbal, A., Dernst, A., Lovotti, M., Mangan, M., McManus, R. M., & Latz, E. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-022-00922-w · Cited by 259
Self-citationThe role of inflammasomes in human diseases and their potential as therapeutic targets
Yao, J., Sterling, K., Wang, Z., Zhang, Y., & Song, W. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01687-y · Cited by 260
The NLRP3 Inflammasome in Alzheimer’s Disease
Tan, M., Yu, J., Jiang, T., Zhu, X., & Tan, L. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8475-x · Cited by 249
Ma, Q. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000629 · Cited by 260
Role of neuroinflammation in neurodegeneration: new insights
McManus, R. M., & Heneka, M. T. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0241-2 · Cited by 258
Self-citationThe microglial NLRP3 inflammasome is activated by amyotrophic lateral sclerosis proteins
Deora, V., Lee, J. D., Albornoz, E. A., McAlary, L., Jagaraj, C. J., Robertson, A. A. B., Atkin, J. D., Cooper, M. A., Schroder, K., Yerbury, J. J., et al. (2020) · Glia · doi:10.1002/glia.23728 · Cited by 245
P2X7 receptor and the NLRP3 inflammasome: Partners in crime
Pelegrín, P. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114385 · Cited by 253
Neurosteroids as regulators of neuroinflammation
Yılmaz, C., Karali, K., Fodelianaki, G., Gravanis, A., Chavakis, T., Charalampopoulos, I., & Alexaki, V. I. (2019) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2019.100788 · Cited by 261
Zhang, Z., Liu, X., Schroeder, J. P., Chan, C.-B., Song, M., Yu, S. P., Weinshenker, D., & Ye, K. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2013.243 · Cited by 242
Zamyatina, A., & Heine, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.585146 · Cited by 254
TDP-43 activates microglia through NF-κB and NLRP3 inflammasome
Zhao, W., Beers, D. R., Bell, S., Wang, J., Wen, S., Baloh, R. H., & Appel, S. H. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.07.019 · Cited by 241
NLRP3 Inflammasome Inhibitor Ameliorates Amyloid Pathology in a Mouse Model of Alzheimer’s Disease
Yin, J., Zhao, F., Chojnacki, J. E., Fulp, J., Klein, W. L., Zhang, S., & Zhu, X. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0467-9 · Cited by 244
Inflammasome Priming in Sterile Inflammatory Disease
Patel, M. N., Carroll, R. G., Galván-Peña, S., Mills, E. L., Olden, R., Triantafilou, M., Wolf, A. I., Bryant, C. E., Triantafilou, K., & Masters, S. L. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.12.007 · Cited by 241
Immune hyperreactivity of Aβ plaque-associated microglia in Alzheimer's disease
Yin, Z., Raj, D., Saiepour, N., Van Dam, D., Brouwer, N., Holtman, I. R., Eggen, B. J. L., Möller, T., Tamm, J. A., Abdourahman, A., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.03.021 · Cited by 238
Metadata
- Authors
- Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., Gelpi, E., Halle, A., Korte, M., Latz, E., & Golenbock, D. T.
- Affiliations
- University of Bonn (DE)
- Technische Universität Braunschweig (DE)
- University of Massachusetts Chan Medical School (US)
- Center of Advanced European Studies and Research (DE)
- Corresponding author
- Heneka, Michael T.
- Latz, Eicke
- Golenbock, Douglas T.
- ORCID
- Venue
- Nature
- Published
- 2012-12-19
- Volume
- 493
- Issue
- 7434
- Pages
- 674-678
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3812809
- OpenAlex
- W1993976394
- Semantic Scholar
- 3a962c33176c94bc0dd8bfea4ebe2eb83be8a01e
- Cited by
- 2,898
- References
- 34
- Citations by year
- 2026: 274 · 2025: 270 · 2024: 273 · 2023: 270 · 2022: 306 · 2021: 314 · 2020: 261 · 2019: 203 · 2018: 187 · 2017: 147 · 2016: 117 · 2015: 112 · 2014: 99 · 2013: 62
- FWCI
- 35.07
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
- HZI (Helmholtz Centre for Infection Research) (submittedVersion)
- The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Max Planck Digital Library (submittedVersion)
- DZNE Pub (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- National Institutes of Health
- Genentech
- National Heart, Lung, and Blood Institute (R01HL093262)
- National Institute of General Medical Sciences (R01GM054060)
- National Institute of Allergy and Infectious Diseases (U19AI084048, R01AI083713)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- NLRP3 inflammasome, caspase-1, Alzheimer's disease, amyloid-beta, APP/PS1 mice, microglia, neuroinflammation, IL-1β, amyloid-beta clearance, spatial memory, NLRP3 knockout mice, cognitive impairment, therapeutic target
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Aged, Aged, 80 and over, Alzheimer Disease, Animals, Behavior, Animal, Brain, Carrier Proteins, Humans, Memory, Mice, Inbred C57BL, Mice, Transgenic, Phagocytosis, Gene Expression Regulation, Enzymologic, Amyloid beta-Peptides, Caspase 1, Mice, Nitric Oxide Synthase Type II, Interleukin-1beta, Inflammasomes, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
